Barnes & Thornburg Advises GNQ Insilico Inc. on $500M De-SPAC IPO Transaction With IB Acquisition Corp.

The transaction values GNQ Insilico at $500 million, with current GNQ shareholders having the ability to earn additional consideration through revenue earnout and share price earnout provisions.

Founded in 2023, GNQ Insilico aims to revolutionize drug development by leveraging technologies such as artificial intelligence, digital twin technology, advanced biological modeling and quantum computing to enable precision medicine at scale. This approach is intended to expedite the discovery, development and optimization of new therapeutics, ultimately improving patient outcomes across health conditions.

The BT team is led by partners Jay Knight and Tim Van Hal, which also includes partners Scott Budlong, Michele Alexander, Clinton Yu, Brad Love and Brittany McCants, associates Emily Gould, Caylyn Harvey, and Anna Gurr, and law clerk Marion Cosey.

Read the transaction press release here.